Zanolimumab

Drug Profile

Zanolimumab

Alternative Names: Anti-CD4 monoclonal antibody HuMax-CD4™; Anti-CD4 monoclonal antibody MDX CD4; HuMax-CD4; MDX CD4; MDX-016

Latest Information Update: 09 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Developer Emergent BioSolutions; Genmab
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 06 Jun 2011 Zanolimumab licensed to Emergent BioSolutions worldwide
  • 31 Dec 2010 Suspended - Phase-III for Cutaneous T-cell lymphoma in European Union (IV)
  • 31 Dec 2010 Suspended - Phase-III for Cutaneous T-cell lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top